ARID1A and ovarian carcinoma: In analyzing the correlations between mutations or other aberrations in ARID1A and BAF250a expression in ovarian cancer and contiguous AE, eight studies detected possible correlations [11,33,34,37,43,44,46,49], with a rate of ARID1A mutations and BAF250A loss of expression in AE ranging from 23.8 to 100%.